Novavax Inc. said Thursday it will conduct an early-stage study on its potential vaccine for respiratory syncytial virus, following the resolution of a Food and Drug Administration request.
Respiratory syncytial virus, or RSV, infects about 8.5 million adults every year and can cause severe pneumonia in the elderly, Novavax has said. RSV is the most common cause of lower respiratory tract illnesses in infants and young children.
The early-stage study was delayed in November when the FDA requested more information on the chemistry, manufacturing and controls for the drug. The company said the regulatory request has been resolved and the study will now move forward.
Shares of Novavax rose 4 cents to $2.60 in morning trading.